Clarity operates in the growing gamma-stimulation segment for Alzheimer’s, using 40 Hz audiovisual entrainment to target disease-modifying pathways. It sits alongside Cognito Therapeutics but remains earlier-stage, with differentiation primarily around device design and delivery rather than underlying biological mechanism.